BNP Paribas Asset Management
AKBA icon

BNP Paribas Asset Management’s Akebia Therapeutics AKBA Stock Holding History

BNP Paribas Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,249
Closed -$7K – 2260
2025
Q4 		$7K Buy
4,249
+2,315
+120% +$4.85K ﹤0.01% 2238
2025
Q3 		$5K Buy
+1,934
New +$6.43K ﹤0.01% 1810

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

BNP Paribas Asset Management's AKBA Position: Q1 2026 in Review

BNP Paribas Asset Management sold out of Akebia Therapeutics (AKBA) in Q1 2026, closing a stake of 4,249 shares — an estimated $7K sold.

BNP Paribas Asset Management first reported a position in AKBA in Q3 2025 and held it in 2 quarters. The position peaked at $7K in Q4 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • BNP Paribas Asset Management reported no remaining Akebia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • BNP Paribas Asset Management sold 4,249 Akebia Therapeutics shares in Q1 2026, an estimated $7K.
  • BNP Paribas Asset Management first reported a position in Akebia Therapeutics in Q3 2025 and held it in 2 quarters.
  • BNP Paribas Asset Management's Akebia Therapeutics position peaked at $7K in Q4 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.